Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pacific Edge Limited ( (PFGTF) ) has provided an update.
Pacific Edge Limited held its Annual Shareholders’ Meeting in Auckland, focusing on its advancements in cancer diagnostics, particularly through its Cxbladder tests. The company emphasized its commitment to improving patient outcomes and efficiency in clinical workflows, supported by over 20 years of research and numerous peer-reviewed publications. The inclusion of Cxbladder Triage in the American Urological Association’s Microhematuria Guideline highlights its growing acceptance and utility in the medical community. With over 130,000 tests ordered by more than 5,000 urologists in the US, and significant accessibility in New Zealand, Pacific Edge is well-positioned to continue its impact in the cancer diagnostics industry.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. Headquartered in Dunedin, New Zealand, the company offers its Cxbladder suite of non-invasive genomic urine tests, which are designed for risk stratification of urothelial cancer. These tests are available globally, including in the US, Australasia, Israel, and various markets in Asia and South America.
Find detailed analytics on PFGTF stock on TipRanks’ Stock Analysis page.